Molecular profiling residual disease from early stage HER2 positive breast cancer treated with neoadjuvant chemo- and anti-HER2 therapy

采用新辅助化疗和抗 HER2 疗法治疗的早期 HER2 阳性乳腺癌残留疾病的分子谱分析

• 批准号: nhmrc : GNT1123212
• 负责人: Prof Sherene Loi
• 金额: $ 46.71万
• 依托单位国家: 澳大利亚
• 项目类别: Project Grants
• 财政年份: 2017
• 资助国家: 澳大利亚
• 起止时间: 2017-01-01 至 无数据
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/molecular-profiling-residual-her2-therapy/1347325
• 关键词: Molecular; profiling; residual; disease; early

Chemotherapy given prior to surgery can often inform us if a breast tumour is sensitive or resistant to therapy by the amount of disease remaining at time of surgery. We have further shown that the immune response is also important in these patients. In this study we propose to analyse the tumour samples that remain after chemotherapy in order to understand possible resistance mechanisms as well as how the immunity influences survival of HER2-positive breast cancer patients

手术前进行的化学疗法通常可以告知我们乳腺肿瘤是否对手术时仍保持的疾病量敏感或抗治疗。我们进一步表明，免疫反应在这些患者中也很重要。在这项研究中，我们建议分析化学疗法后保留的肿瘤样品，以了解可能的抗药性机制，以及免疫力如何影响HER2阳性乳腺癌患者的存活率